Organon (OGN) Income from Continuing Operations (2020 - 2026)

Organon (OGN) recorded quarterly Income from Continuing Operations of 146000000.0 in Q1 2026, up 171.22% quarter-over-quarter from 205000000.0 in Q4 2025, and up 67.82% on a YoY basis from 87000000.0 in Q1 2025.

Organon (OGN) Income from Continuing Operations (2020 - 2026) Analysis & Trends

Organon's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 146000000.0 for Q1 2026.

  • In Q1 2026, Income from Continuing Operations rose 67.82% year-over-year to 146000000.0; the TTM figure through Mar 2026 stood at 246000000.0 (down 67.2% YoY), while the FY2025 annual figure was 187000000.0, down 78.36% from the prior year.
  • Income from Continuing Operations was 146000000.0 for Q1 2026 at Organon, up from 205000000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 546000000.0 in Q4 2023 to a low of 205000000.0 in Q4 2025.
  • Historically, Income from Continuing Operations has averaged 210000000.0 across 5 years, with a median of 195000000.0 in 2024.
  • The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 518.97% in 2024, then sank 288.07% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 541000000.0 in 2022, then gained by 0.92% to 546000000.0 in 2023, then plunged by 80.04% to 109000000.0 in 2024, then tumbled by 288.07% to 205000000.0 in 2025, then jumped by 171.22% to 146000000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 146000000.0 (Q1 2026), 205000000.0 (Q4 2025), and 160000000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Gsk 93,026,132.38 Bn 93,026,127.42 Bn 7.76 Bn 3.30 Bn
2 Eli Lilly 1,022.62 Bn 1,017.34 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 570.65 Bn 548.59 Bn 15.96 Bn 5.24 Bn
4 AbbVie 398.73 Bn 389.38 Bn 10.78 Bn 697.00 Mn
5 Merck 295.53 Bn 289.88 Bn 12.09 Bn -4.21 Bn
6 Amgen 186.30 Bn 174.26 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn 2.02 Bn
8 Pfizer 146.09 Bn 133.32 Bn -1.21 Bn 2.71 Bn
9 Bristol Myers Squibb 114.98 Bn 104.53 Bn 8.07 Bn 2.68 Bn
10 Organon 3.49 Bn 2.37 Bn 783.00 Mn 146.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 146.00 Mn
Dec 31, 2025 -205.00 Mn
Sep 30, 2025 160.00 Mn
Jun 30, 2025 145.00 Mn
Mar 31, 2025 87.00 Mn
Dec 31, 2024 109.00 Mn
Sep 30, 2024 359.00 Mn
Jun 30, 2024 195.00 Mn
Mar 31, 2024 201.00 Mn
Dec 31, 2023 546.00 Mn
Sep 30, 2023 58.00 Mn
Jun 30, 2023 242.00 Mn
Mar 31, 2023 177.00 Mn
Dec 31, 2022 541.00 Mn
Sep 30, 2022 227.00 Mn
Jun 30, 2022 234.00 Mn
Mar 31, 2022 348.00 Mn
Dec 31, 2021 202.00 Mn
Sep 30, 2021 323.00 Mn
Jun 30, 2021 431.00 Mn